Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,870 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival following allogeneic transplant in patients with myelofibrosis.
Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W. Gowin K, et al. Among authors: nakamura r. Blood Adv. 2020 May 12;4(9):1965-1973. doi: 10.1182/bloodadvances.2019001084. Blood Adv. 2020. PMID: 32384540 Free PMC article.
Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.
Nakamura R, Battiwalla M, Solomon S, Follmann D, Chakrabarti S, Cortez K, Hensel N, Childs R, Barrett AJ. Nakamura R, et al. Biol Blood Marrow Transplant. 2004 Jan;10(1):49-57. doi: 10.1016/j.bbmt.2003.08.011. Biol Blood Marrow Transplant. 2004. PMID: 14752779 Free article.
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.
Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, Kwok C, Yamauchi D, Anderson AL, Falk P, Krishnan A, Kirschbaum M, Kogut N, Nakamura R, O'donnell M, Parker P, Popplewell L, Pullarkat V, Rodriguez R, Sahebi F, Smith E, Snyder D, Stein A, Spielberger R, Zain J, White C, Raubitschek A. Nademanee A, et al. Among authors: nakamura r. Blood. 2005 Oct 15;106(8):2896-902. doi: 10.1182/blood-2005-03-1310. Epub 2005 Jul 7. Blood. 2005. PMID: 16002426 Free PMC article. Clinical Trial.
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L, Zain J, Patane K, Kogut N, Nakamura R, Sarkodee-Adoo C, Forman SJ. Rodriguez R, et al. Among authors: nakamura r. Biol Blood Marrow Transplant. 2006 Dec;12(12):1326-34. doi: 10.1016/j.bbmt.2006.08.035. Biol Blood Marrow Transplant. 2006. PMID: 17162215 Free article.
Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates.
Nakamura R, Auayporn N, Smith DD, Palmer J, Sun JY, Schriber J, Pullarkat V, Parker P, Rodriguez R, Stein A, Rosenthal J, Wang S, Karanas C, Gaal K, Senitzer D, Forman SJ. Nakamura R, et al. Biol Blood Marrow Transplant. 2008 Apr;14(4):449-57. doi: 10.1016/j.bbmt.2008.02.005. Biol Blood Marrow Transplant. 2008. PMID: 18342788 Free PMC article.
Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.
Snyder DS, Palmer J, Gaal K, Stein AS, Pullarkat V, Sahebi F, Vora N, Nakamura R, Forman SJ. Snyder DS, et al. Among authors: nakamura r. Biol Blood Marrow Transplant. 2010 Feb;16(2):281-6. doi: 10.1016/j.bbmt.2009.09.020. Epub 2009 Sep 26. Biol Blood Marrow Transplant. 2010. PMID: 19786111 Free PMC article.
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, Snyder D, Pullarkat V, Kogut N, Rosenthal J, Smith E, Karanes C, O'Donnell M, Krishnan AY, Senitzer D, Forman SJ. Rodriguez R, et al. Among authors: nakamura r. Blood. 2010 Feb 4;115(5):1098-105. doi: 10.1182/blood-2009-03-207563. Epub 2009 Nov 19. Blood. 2010. PMID: 19965688 Free PMC article. Clinical Trial.
2,870 results